Guselkumab Dose 1 ( DrugBank: Guselkumab )

3 diseases

51. 全身性強皮症

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2051200133	31/03/2021	12/02/2021	A study of Guselkumab in Participants with Systemic Sclerosis	A Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in ...	Scleroderma, Systemic	Group A: Guselkumab Dose 1 Guselkumab Dose 1will be administered intravenously. Group A: Guselkumab Do ...	Numaguchi Hirotaka	NULL	Recruiting	>= 18age old	<= 75age old	Both	56	Phase 2	Japan
2	NCT04683029 (ClinicalTrials.gov)	February 24, 2021	22/12/2020	A Study of Guselkumab in Participants With Systemic Sclerosis	A Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in ...	Scleroderma, Systemic	Drug: Guselkumab Dose 1;Drug: Guselkumab Dose 2;Drug: Placebo	Janssen Pharmaceutical K.K.	NULL	Recruiting	18 Years	75 Years	All	56	Phase 2	Japan

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05197049 (ClinicalTrials.gov)	January 17, 2022	17/1/2022	A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn' ...	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef ...	Crohn Disease	Drug: Guselkumab Dose 1;Drug: Guselkumab Dose 2;Drug: Guselkumab Dose 3;Drug: Placebo	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	N/A	All	318	Phase 3	United States;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;G ...
2	NCT03466411 (ClinicalTrials.gov)	April 13, 2018	8/3/2018	A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active ...	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter P ...	Crohn's Disease	Drug: Guselkumab Dose 1;Drug: Guselkumab Dose 2;Drug: Guselkumab Dose 3;Drug: Guselkumab Dose 4;Drug ...	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	N/A	All	2000	Phase 2/Phase 3	United States;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Col ...

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-194980	22/5/2020	30/09/2019	A Study of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis	A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to ...	Ulcerative Colitis	Intervention name : Guselkumab INN of the intervention : Guselkumab Dosage And administration of the i ...	Janssen Pharmaceutical K.K.	NULL	recruiting	18		BOTH	1000	Phase 2-3	Japan, Asia except Japan, North America, Europe
2	NCT03662542 (ClinicalTrials.gov)	November 20, 2018	6/9/2018	A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants ...	A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concep ...	Colitis, Ulcerative	Drug: Guselkumab Dose 1;Drug: Guselkumab Dose 2;Drug: Golimumab Dose 1;Drug: Golimumab Dose 2;Drug: ...	Janssen Research & Development, LLC	NULL	Completed	18 Years	65 Years	All	214	Phase 2	United States;Argentina;Australia;Brazil;Germany;Mexico;Poland;Russian Federation;Ukraine